Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberto Chang

Interventional Pain Medicine Hoover, AL Medical Doctor

NPI 1669608923 CMS profile 467925

4515 Southlake Pkwy Ste 200, Hoover, AL 35244

Open in the dashboard

General payments

$13,281

624 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberto Chang of Hoover, AL is reported in the CMS Open Payments database as having received $13,281 across 624 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,075 108
2024 General $1,820 104
2023 General $1,630 97
2022 General $1,244 82
2021 General $2,455 92
2020 General $733 36
2019 General $1,324 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Chang
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Roberto Chang were reported at $4,075. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Roberto Chang Interventional Pain Medicine median Middle half National median
2019 $1,324 $684 $216–$2,079 $163
2020 $733 $382 $122–$1,109 $114
2021 $2,455 $552 $167–$1,554 $132
2022 $1,244 $605 $187–$1,924 $149
2023 $1,630 $671 $195–$1,915 $160
2024 $1,820 $684 $206–$1,837 $164
2025 $4,075 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,924 235 payments
  2. MML US, Inc. $1,699 9 payments
  3. BIOTRONIK NRO, Inc. $871 24 payments
  4. Collegium Pharmaceutical, Inc. $703 49 payments
  5. Pfizer Inc. $618 37 payments
  6. Forte Bio-Pharma LLC $511 33 payments
  7. AbbVie, Inc. $336 29 payments
  8. SPR Therapeutics, Inc $322 16 payments
  9. Abbott Laboratories $292 17 payments
  10. Scilex Pharmaceuticals Inc. $273 18 payments
  11. Other $2,732 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,403 617 payments
  2. Travel and Lodging $1,866 5 payments
  3. Education $12 2 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $1,951 89 payments
  2. ReActiv8 $1,699 9 payments
  3. WAVEWRITER ALPHA $1,316 25 payments
  4. Prospera $871 24 payments
  5. SPECTRA WAVEWRITER $689 51 payments
  6. NURTEC ODT $518 29 payments
  7. ZAVZPRET $468 26 payments
  8. PROLATE Pain $430 32 payments
  9. PROLATE Pain $430 32 payments
  10. PROLATE Pain $430 32 payments
  11. Other $6,993 426 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

10,887

Median for Interventional Pain Management: 1,220

Drug cost

$746,469

Median for Interventional Pain Management: $39,344

Branded share of claims

40%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 78 $69,131
Prolate Oxycodone Hcl/Acetaminophen Brand 20 $68,467
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,637 $67,215
Nucynta Er Tapentadol Hcl Brand 42 $55,684
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,783 $53,233
Buprenorphine Generic 199 $51,224
Nucynta Tapentadol Hcl Brand 50 $49,838
Fentanyl Generic 288 $46,161
Relistor Methylnaltrexone Bromide Brand 16 $36,092
Movantik Naloxegol Oxalate Brand 57 $23,835

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$321,068

Of which drugs: $11,405

Medicare patients

352

Average age 68

Services billed

8,944

225 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 41%
Diabetes 34%
Ischemic heart disease 29%
Chronic kidney disease 26%
COPD 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 93 1,854 $159
Injection, fentanyl citrate, 0.1 mg J3010 Office 27 32 $22
Injection, propofol, 10 mg J2704 Office 11 198 $19
Injection, midazolam hydrochloride, per 1 mg J2250 Office 29 115 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $132
$132 20 —
NURTEC ODT
  • PFIZER INC. $126
$126 — —
ZAVZPRET
  • PFIZER INC. $126
$126 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $108
$108 30 —
ZTLido
  • Scilex Pharmaceuticals Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record